Johnson & Johnson (JNJ) Advances Bladder Cancer Treatment with 89% Response Rate [Yahoo! Finance]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Yahoo! Finance
from a Phase 1 study of an innovative intravesical drug-releasing mechanism with erdafitinib (Erda-iDRS) in patients with non-muscle-invasive bladder cancer who had specific fibroblast growth factor receptor mutations. Pixabay/Public Domain According to the company, the trial met its major safety goals. The intermediate-risk sample of 62 patients had an 89% complete response rate, with a median length of 18 months. Johnson & Johnson (NYSE:JNJ) also stated on March 12 that the FDA had approved its TECNIS PureSee IOL, an expanded depth of focus intraocular lens for cataract surgery. The lens is associated with JNJ's TECNIS portfolio, which also includes the TECNIS Odyssey and TECNIS Eyhance IOLs. The company stated that millions of patients around the world receive TECNIS lenses each year as part of their cataract treatment. Johnson & Johnson (NYSE:JNJ) is a diversified healthcare company. It operates through three main segments: Innovative Medicine, MedTech, and Consumer Health
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Protagonist Partners With Johnson & Johnson To Compete With AbbVie's Skyrizi [Seeking Alpha]Seeking Alpha
- ???????????????????? : ???????????????2035??3?3534?????? CAGR9%??????????????????????????? [CNET News]CNET News
- Protagonist Therapeutics Soars as FDA Approves ICOTYDE for Plaque Psoriasis, Triggers $50M Milestone [Yahoo! Finance]Yahoo! Finance
- Jim Cramer on Johnson & Johnson: “It's a Textbook Slowdown Stock” [Yahoo! Finance]Yahoo! Finance
- Pulse Biosciences Touts 96% 12-Month Rhythm Control, Targets Q2 Start for U.S. AF IDE Study [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 1/21/26 - Beat
JNJ
Sec Filings
- 3/18/26 - Form 13F-HR/A
- 3/18/26 - Form 13F-HR/A
- 3/12/26 - Form 4
- JNJ's page on the SEC website